GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » Retained Earnings

Bluejay Diagnostics (Bluejay Diagnostics) Retained Earnings : $-29.28 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Bluejay Diagnostics's retained earnings for the quarter that ended in Mar. 2024 was $-29.28 Mil.

Bluejay Diagnostics's quarterly retained earnings declined from Sep. 2023 ($-24.65 Mil) to Dec. 2023 ($-26.95 Mil) and declined from Dec. 2023 ($-26.95 Mil) to Mar. 2024 ($-29.28 Mil).

Bluejay Diagnostics's annual retained earnings declined from Dec. 2021 ($-7.70 Mil) to Dec. 2022 ($-17.00 Mil) and declined from Dec. 2022 ($-17.00 Mil) to Dec. 2023 ($-26.95 Mil).


Bluejay Diagnostics Retained Earnings Historical Data

The historical data trend for Bluejay Diagnostics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics Retained Earnings Chart

Bluejay Diagnostics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
-2.93 -4.21 -7.70 -17.00 -26.95

Bluejay Diagnostics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.54 -22.35 -24.65 -26.95 -29.28

Bluejay Diagnostics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Bluejay Diagnostics  (NAS:BJDX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Traded in Other Exchanges
N/A
Address
360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720
Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.
Executives
Svetlana Dey director, 10 percent owner 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey director, 10 percent owner, officer: Chief Technology Officer 360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally officer: CFO 66 MELANIE LANE, SYOSSET NY 11791
Jason Cook officer: Chief Technology Officer 360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher officer: Chief Financial Officer 67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth director, 10 percent owner 4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder officer: Chief Financial Officer 360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani director C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman director 109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase director 39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089